Table 1.
Summary of Repurposed Drug Prices for COVID-19 and Estimated Availabilitya
| Drug, Duration, and Dose | Highest List Price | Lowest List Price | Estimated Production Cost (Course) | FDA Approval | NICE Approval | WHO Approval | Estimated Current Availabilityb |
|---|---|---|---|---|---|---|---|
| Dexamethasone | US $26.47 | US $0.98 | US $2.58 | Yes | Yes | Yes | 7.4 million treatment courses |
| IV 10 days | UK | Vietnam | |||||
|
6 mg OD (60 mg total) | |||||||
| Dexamethasone | US $30.79 | US $0.22 | US $0.19 | Yes | Yes | Yes | |
|
PO 10 days 6 mg OD (60 mg total) |
UK | Peru | |||||
| Baricitinib | US $2326.38 | US $6.67 | --- | No (EUA) [12] | No | No | NA |
|
PO 14 days 4 mg OD (56 mg total) |
USA Pharmacy |
Bangladesh | |||||
| Sarilumab | US $4850.90 | US $875.70 | --- | No | Yes | Yes | NA |
|
IV once only 400 mg single dose |
USA (Veterans) |
France | |||||
| Tocilizumab | US $3625.14 | US $410.59 | --- | No (EUA) [47] | Yes | Yes | NA |
|
IV once only 600 mg single dose |
USA (Pharmacy) | Australia | |||||
| Budesonide | US $45.74 | US $3.49 | US $4.34 per inhaler | No | No (off-label use advised) [48] | No | 80 million inhalers |
| INH (inhaler price) | Norway | India | |||||
| 20 mg device (100×200 mcg/dose) | |||||||
| Casirivimab and imdevimab (Ronapreve) | NA | NA | NA | No (EUA) | No (off-label use advice) [48] | No | NA |
|
IV once only 2400 mg/1200 mg |
Abbreviations: BD, twice per day; COVID-19, coronavirus disease 2019; EUA, emergency use authorization; FDA, US Food and Drug Administration; IV, intravenous; NA, not applicable; NICE, United Kingdom National Institute of Health and Care Excellence; OD, once daily; PO, by mouth; UK, United Kingdom; WHO, World Health Organization.
Summary of list prices, estimated production co
sts, and current availability of potential COVID-19 drugs selected for analysis. Baricitinib only has EUA to be given in combination with remdesivir.
In most recent 12-month period, based on India active pharmaceutical ingredients (API) export volumes only. Current availability may be an underestimation because it is not based on global API availability data.